genome
Scope
Date
~
-
Bio & Pharma
Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials
Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...
Sep 20, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's NGeneBio establishes US corporation NGeneBioAI
South Korean medical diagnostic company NGeneBio Co. announced on Monday that it has established an artificial intelligence (AI) precision diagnosti...
Jul 24, 2023 (Gmt+09:00)
-
Pharamaceuticals
Korea’s Genome & Company aims US CMO market
South Korea’s microbiome medicine developer Genome & Company geared up for entering the U.S. market to boost profits and make inroads into...
Sep 09, 2021 (Gmt+09:00)
language